Synthetic Biologics Receives New Coverage from Analysts at Maxim Group (SYN)
Maxim Group began coverage on shares of Synthetic Biologics (NYSE:SYN) in a research note issued on Monday, StockRatingsNetwork reports. The firm set a “buy” rating and a $3.00 price target on the stock. Maxim Group’s price objective points to a potential upside of 75.44% from the stock’s previous close.
Synthetic Biologics (NYSE:SYN) opened at 1.71 on Monday. Synthetic Biologics has a one year low of $1.34 and a one year high of $2.55. The stock has a 50-day moving average of $1.54 and a 200-day moving average of $1.59. The company’s market cap is $76.4 million.
Synthetic Biologics (NYSE:SYN) last posted its quarterly earnings results on Wednesday, August 14th. The company reported ($0.06) EPS for the quarter, meeting the Thomson Reuters consensus estimate of ($0.06). On average, analysts predict that Synthetic Biologics will post $-0.22 earnings per share for the current fiscal year.
Synthetic Biologics, Inc, formerly Adeona Pharmaceuticals, Inc, is a biotechnology company focused on the development of synthetic deoxyribonucleic acid (NYSE:SYN)-based therapeutics and disease-modifying medicines for serious illnesses.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.